Rapport Therapeutics Statistics
Total Valuation
RAPP has a market cap or net worth of $1.41 billion. The enterprise value is $904.85 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RAPP has 47.66 million shares outstanding. The number of shares has increased by 190.80% in one year.
| Current Share Class | 47.66M |
| Shares Outstanding | 47.66M |
| Shares Change (YoY) | +190.80% |
| Shares Change (QoQ) | +7.02% |
| Owned by Insiders (%) | 4.65% |
| Owned by Institutions (%) | 72.81% |
| Float | 30.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.75 |
| P/TBV Ratio | 2.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 36.37, with a Debt / Equity ratio of 0.02.
| Current Ratio | 36.37 |
| Quick Ratio | 35.84 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.41% and return on invested capital (ROIC) is -16.23%.
| Return on Equity (ROE) | -23.41% |
| Return on Assets (ROA) | -15.89% |
| Return on Invested Capital (ROIC) | -16.23% |
| Return on Capital Employed (ROCE) | -21.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.42M |
| Employee Count | 69 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.83% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +36.83% |
| 50-Day Moving Average | 26.89 |
| 200-Day Moving Average | 16.65 |
| Relative Strength Index (RSI) | 60.85 |
| Average Volume (20 Days) | 388,206 |
Short Selling Information
The latest short interest is 2.00 million, so 4.20% of the outstanding shares have been sold short.
| Short Interest | 2.00M |
| Short Previous Month | 1.93M |
| Short % of Shares Out | 4.20% |
| Short % of Float | 6.59% |
| Short Ratio (days to cover) | 5.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -110.11M |
| Pretax Income | -97.70M |
| Net Income | -97.70M |
| EBITDA | -109.10M |
| EBIT | -110.11M |
| Earnings Per Share (EPS) | -$2.72 |
Full Income Statement Balance Sheet
The company has $513.03 million in cash and $11.87 million in debt, giving a net cash position of $501.15 million or $10.51 per share.
| Cash & Cash Equivalents | 513.03M |
| Total Debt | 11.87M |
| Net Cash | 501.15M |
| Net Cash Per Share | $10.51 |
| Equity (Book Value) | 511.62M |
| Book Value Per Share | 10.74 |
| Working Capital | 506.34M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$77.22 million and capital expenditures -$673,000, giving a free cash flow of -$77.89 million.
| Operating Cash Flow | -77.22M |
| Capital Expenditures | -673,000 |
| Free Cash Flow | -77.89M |
| FCF Per Share | -$1.63 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |